Related Experiment Videos
[Autophagy, autoimmunity and autoimmune diseases]
1CNRS, Immunopathologie et chimie thérapeutique, Laboratoire d'Excellence Medalis, Institut de biologie moléculaire et cellulaire, 15, rue René Descartes, 67000 Strasbourg, France - Institut d'études avancées de l'université de Strasbourg (USIAS), Strasbourg, France.
Medecine Sciences : M/S
|April 4, 2017
Summary
The novel phosphopeptide P140 (Lupuzor) shows promise for treating systemic lupus by targeting autophagy pathways in lymphocytes. This therapy may correct immune abnormalities without side effects, offering a new hope for lupus patients.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Autoimmune diseases like systemic lupus erythematosus (SLE) arise from self-directed immune responses.
- Defective autophagy pathways in lymphocytes are implicated in lupus pathogenesis.
- Current SLE treatments carry significant side effects.
Purpose of the Study:
- To investigate the therapeutic potential of the synthetic phosphopeptide P140/Lupuzor for SLE.
- To evaluate P140's mechanism of action on autophagy and T cell responses in lupus models.
Main Methods:
- Utilized lupus mouse models to assess P140 treatment.
- Analyzed autophagy pathway activity in lymphocytes.
- Evaluated T and B cell populations and function.
- Monitored clinical and biological features of lupus.
Main Results:
- P140 targets hyperactivated chaperone-mediated autophagy in lupus.
- P140 reduces the presentation of autoantigenic peptides to T cells.
- Treatment with P140 reversed immunological abnormalities in T and B cells.
- P140 treatment ameliorated clinical and biological features of lupus in mice.
Conclusions:
- P140/Lupuzor is a promising therapeutic candidate for SLE with a favorable safety profile.
- Targeting chaperone-mediated autophagy with P140 offers a novel strategy for SLE treatment.
- P140 effectively modulates immune responses implicated in lupus pathogenesis.